• Select Article Type
  • Abstract Supplements
  • Blood Group Review
  • Call to Arms
  • Hypothesis
  • In Memoriam
  • Interview
  • Introduction
  • Letter to the Editor
  • Short Report
  • abstract
  • Abstracts
  • Article
  • book-review
  • case-report
  • case-study
  • Clinical Practice
  • Commentary
  • Conference Presentation
  • conference-report
  • congress-report
  • Correction
  • critical-appraisal
  • Editorial
  • Editorial Comment
  • Erratum
  • Events
  • Letter
  • Letter to Editor
  • mini-review
  • minireview
  • News
  • non-scientific
  • Obituary
  • original-paper
  • original-report
  • Original Research
  • Pictorial Review
  • Position Paper
  • Practice Report
  • Preface
  • Preliminary report
  • Product Review
  • rapid-communication
  • Report
  • research-article
  • Research Communicate
  • research-paper
  • Research Report
  • Review
  • review -article
  • review-article
  • review-paper
  • Review Paper
  • Sampling Methods
  • Scientific Commentary
  • short-communication
  • short-report
  • Student Essay
  • Varia
  • Welome
  • Select Journal
  • Immunohematology


Article | 01-April-2020

An alloantibody to a highprevalence MNS antigen in a person with a GP.JL/Mk phenotype

The low-prevalence MNS blood group antigenTSEN is located at the junction of glycophorinA (GPA) to glycophorin B (GPB) in several hybrid glycophorin molecules. Extremely rare people have RBCs with a double dose of theTSEN antigen and have made an antibody to a high-prevalence MNS antigen. We report the first patient who is heterozygous for GYP.JL and Mk. During prenatal tests,an alloantibody to a high-prevalence antigen was detected in the serum of a 21-year-old Hispanic woman. The antibody

John Ratliff, Susan Veneman, Joan Ward, Christine Lomas-Francis, Kim Hue-Roye, Randall W. Velliquette, Laima Sausais, Twilla Maldonado, Janet Miyamoto, Yolanda Martin, David Slater, Marion E. Reid

Immunohematology, Volume 23 , ISSUE 4, 146–149

Case report | 09-October-2019

A LU:-16 individual with antibodies

Carole Éthier, Cynthia Parent, Anne-Sophie Lemay, Nadia Baillargeon, Geneviève Laflamme, Josée Lavoie, Josée Perreault, Maryse St-Louis

Immunohematology, Volume 33 , ISSUE 3, 110–113

Report | 26-October-2019

A simple approach to screen rare donors in Brazil

Carine Prisco Arnoni, Flavia R.M. Latini, Janaína Guilhem Muniz, Rosangela Duarte de Medeiros Person, Tatiane Aparecida de Paula Vendrame, Diana Gazito, Lilian Castilho

Immunohematology, Volume 31 , ISSUE 1, 20–23

Case report | 09-October-2019

Acute hemolytic transfusion reaction attributed to anti-Ata

Jay S. Raval, Sarah K. Harm, Bethann Wagner, Darrell J. Triulzi, Mark H. Yazer

Immunohematology, Volume 32 , ISSUE 4, 140–142

Case report | 09-October-2019

A suspected delayed hemolytic transfusion reaction mediated by anti-Joa

Ryan P. Jajosky, Wendy C. Lumm, Scott C. Wise, Roni J. Bollag, James F. Shikle

Immunohematology, Volume 33 , ISSUE 2, 73–75

Article | 10-April-2021

Acute hemolytic transfusion reaction caused by anti-Yta

M. Raos, N. Thornton, M. Lukic, B. Golubic Cepulic

Immunohematology, Volume 37 , ISSUE 1, 13–17

Article | 16-October-2019

Anti-Vel alloimmunization and severe hemolytic disease of the fetus and newborn

risk for HDFN because transplacental passage cannot occur. Linz et al.10 recommended treatment with 2-mercaptoethanol or dithiothreitol to determine whether an IgG component is present. Both IgG and IgM had been detected in our case. A predominance of IgG in our case may well explain the severe degree of HDFN. One should assume that a paternal Vel antigen will be inherited by the fetus, given that Vel is a high-prevalence antigen. Thus, it would appear prudent to institute serial MCA-PSV

K.J. Moise, Y. Morales, M.F. Bertholf, S.N. Rossmann, Y. Bai

Immunohematology, Volume 33 , ISSUE 4, 152–154

Article | 21-April-2020

Analysis of SERF in Thai blood donors

Poonsub Palacajornsuk, Kim Hue-Roye, Oytip Nathalang, Srisurang Tantimavanich, Sasitorn Bejrachandra, Marion Reid

Immunohematology, Volume 21 , ISSUE 2, 66–69

Review | 01-December-2019

EDTA glycine acid treatment of red blood cells

blood group system and for the high-prevalence antigen Era.

Joanne Kosanke

Immunohematology, Volume 28 , ISSUE 3, 95–96

Case report | 01-December-2019

An AQP1 allele associated with Co(a–b–) phenotype

The Colton (CO) blood group system consists of four antigens, Coa, Cob, Co3, and Co4, located on aquaporin-1 (AQP1), with Coa highly prevalent in all populations (99.8%). The Colton null phenotype, Co(a–b–), is very rare, and individuals with this phenotype lack the high-prevalence antigen Co3. To date, only six Co(a–b–) probands have been reported and four silencing alleles characterized. We identified an AQP1-null allele in a white woman with anti-Co3 caused by

Sunitha Vege, Sandra Nance, Donna Kavitsky, Xiaojin Li, Trina Horn, Geralyn Meny, Connie M. Westhoff

Immunohematology, Volume 29 , ISSUE 1, 1–4

Article | 16-February-2021

An update on the Cartwright (Yt) blood group system

M.R. George

Immunohematology, Volume 35 , ISSUE 4, 154–155

Article | 21-April-2020

Novel molecular basis of an Inab phenotype  

The Cromer blood group system consists of ten high-prevalence and three low-prevalence antigens carried on decay-accelerating factor (DAF). DAF is found in the cell membranes of RBCs, granulocytes,platelets,and lymphocytes and is widely represented in other body tissues. Sequence analyses of DNA were performed on a blood sample from a 91-year-old Japanese woman whose serum contained an alloantibody to a high-prevalence antigen in the Cromer blood group system (anti-IFC). A blood sample from her

Kim Hue-Roye, Vivien E. Powell, Gita Patel, Debra Lane, Mariska Maguire, Amy Chung, Marion E. Reid

Immunohematology, Volume 21 , ISSUE 2, 53–55

Review | 09-October-2019

The Augustine blood group system, 48 years in the making

The high-prevalence antigen, Ata, was first identified in 1967, but it was not until 2015 that Ata became AUG1 of a new blood group system, Augustine (AUG). The new system was established after the identification of the gene encoding Ata and the recognition of a null phenotype (AUG:–1,–2) in an At(a–) patient with an antibody (anti-AUG2) reactive with At(a–) red blood cells. The At(a–) phenotype is very rare and, with the exception of the one family with the null

Geoffrey Daniels

Immunohematology, Volume 32 , ISSUE 3, 100–103

Review | 01-December-2019

The LAN blood group system: a review

LAN (Langereis) was officially recognized by the International Society of Blood Transfusion in 2012 as being the 33rd human blood group system. It consists of one single high-prevalence antigen, Lan (LAN1). The ABCB6 protein is the carrier of the Lan blood group antigen. The ABCB6 gene (chromosome 2q36, 19 exons) encodes the ABCB6 polypeptide (ATP-binding cassette protein, subfamily B, member 6), known as a porphyrin transporter. The exceptional Lan– people do not express ABCB6 (Lan null

Thierry Peyrard

Immunohematology, Volume 29 , ISSUE 4, 131–135

Case report | 12-March-2020

Role for serial prenatal anti-Vel quantitative serologic monitoring with 2-ME serum treatment during pregnancy: case report

Anti-Vel is an uncommon antibody to a high-prevalence antigen. Its clinical significance and management in the prenatal setting are not well characterized. We present a case that demonstrates the utility of serial prenatal anti-Vel quantitative serologic monitoring with 2-ME serum treatment during pregnancy. The patient is a 23-year-old Hispanic woman with history of prior pregnancy and prior transfusion who was discovered to have an antibody to the high-prevalence Vel antigen in the first

Walter J. Linz, Judith T. Fueger, Steven Allen, Susan T. Johnson

Immunohematology, Volume 26 , ISSUE 1, 8–10

Case report | 27-April-2020

Case report: massive postpartum transfusion of Jr(a+) red cells in the presence of anti-Jra

Jra is a high-prevalence antigen. The rare Jr(a–) individuals can form anti-Jra after exposure to the Jra antigen through transfusion or pregnancy. The clinical significance of anti-Jra is not well established. This study reports a case of a 31-year-old woman with a previously identified anti-Jra who required massive transfusion of RBCs after developing life-threatening postpartum disseminated intravascular coagulopathy. Despite the emergent transfusion of 15 units of Jra untested RBCs

Shan Yuan, Rosalind Armour, Allison Reid, Khaled F. Abdel-Rahman, Michael Phillips, Dawn M. Rumsey, Theresa Nester

Immunohematology, Volume 21 , ISSUE 3, 97–101

Article | 28-April-2020

Persistent anti-Dra in two pregnancies

The Drori (Dra) antigen is one of the ten high-prevalence antigens of the Cromer blood system, which are carried on decayaccelerating factor (DAF, CD55). The Dr(a–) phenotype was first described in a 48-year-old Jewish woman from Bukhara. Her serum contained an antibody to a high-prevalence antigen named anti-Dra. Most known individuals with the Dr(a–) phenotype are Jews from the geographic area of Bukhara, but individuals from Japan have also been described. Antibodies in the

Naomi Rahimi-Levene, Abraham Kornberg, Gabriela Siegel, Valery Morozov, Eilat Shinar, Orna Asher, Cyril Levene, Vered Yahalom

Immunohematology, Volume 21 , ISSUE 3, 126–128

No Record Found..
Page Actions